Categories
Change Password!
Reset Password!
Pregabalin is a licensed medication for the treating fibromyalgia (FM) in Japan, United States, and 37 other countries.
Fibromyalgia (FM) is a chronic pain disorder with an estimated
prevalence of 1%–10% of the general adult population. Pregabalin is approved
for the pharmacological drug for FM. The number of systematic review and
meta-analysis techniques has also examined the efficacy and safety of
Pregabalin. The purpose of this article was to provide an in-depth,
evidence-based summary of the clinical studies that have evaluated Pregabalin
for the treatment of FM and determined that Pregabalin is a treatment option
for FM.
Pregabalin is a licensed medication for the treating
fibromyalgia (FM) in Japan, United States, and 37 other countries. This study
aimed to present an in-depth, evidence-based review of Pregabalin for FM as
shown in placebo-controlled, randomised, clinical studies, involving
meta-analyses, combination studies, post-hoc analyses of clinical study data,
and open-label extensions.
The Cochrane Library and PubMed were searched using the
terms "Pregabalin" and "Pregabalin AND fibromyalgia",
respectively on two March 2017 with no other date limits set.
A total of 11 placebo-controlled, randomised,
double-blind, clinical studies which involved two-way crossover, a parallel
group and randomised withdrawal designs were identified. One was a neuroimaging
research. Five open-label extensions were also selected. Evidence of
effectiveness was shown over the studies recognised with notable and clinically
appropriate improvements in pain, patient status and sleep quality. Pregabalin
safety and tolerability profile are constant across all the studies identified,
involving in adolescents, with sleepiness and dizziness the most frequent
adverse events proclaimed. Meta-analyses supported the safety and efficacy of
the data. Pregabalin also showed efficacy when used in combination with other
pharmacotherapies. Post-hoc analyses have illustrated the beginning of
Pregabalin efficiency as early as 1-2 days following the initiation of the
treatment, measured the impact of Pregabalin on other phases of sleep beyond
quality, and shown it is capable irrespective of the presence of a wide
diversity of patient demographic and clinical features.
The clinical efficacy of Pregabalin for FM has been
comprehensively illustrated.
Curr Med Res Opin. 2018 Apr 16:1-13.
An evidence-based review of Pregabalin for the treatment of fibromyalgia.
Arnold LM et al.
Comments (0)